UID:
almahu_9949982725702882
Umfang:
1 online resource (206 pages)
Ausgabe:
First edition.
ISBN:
9780443133756
Serie:
Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy Series
Anmerkung:
Intro -- Principles of Immunotherapy in Breast and Gastrointestinal Cancers: Activity, Mechanisms of Resistance and New Sensitizat... -- Copyright -- Cover Image Insert -- Aims and Scope of Series ``Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy´´ -- About the Series Editor -- Aims and scope of the volume -- About the Volume Editor -- Preface -- Contents -- Contributors -- Chapter 1: Mechanisms of resistance to immunotherapy -- Introduction -- The immune system -- The innate immune system -- The adaptive immune system -- How does the immune system control cancer? -- Immunosurveillance -- Immunity cycle -- Historic achievements in immunotherapy -- Overview of immunogenic approaches -- Monoclonal antibodies -- Monoclonal antibodies against tumor antigens -- Monoclonal antibodies against checkpoint molecules -- Antibody drug conjugates -- Nonspecific immunotherapies -- Oncolytic virus therapies -- T-cell therapy -- Cancer vaccines -- Rational of combination treatments -- Resistance factors -- Primary, adaptive, and acquired resistance -- Mechanisms of resistance to immunotherapy -- Tumor cell intrinsic resistance to immunotherapy -- Alterations in antitumor immune response pathways -- Aberrant tumor antigen expression and absence of antigenic proteins -- Antigen presentation pathways -- Alterations in signaling pathways within tumor cells -- Interference with IFNγ signaling pathway -- Aberrant Wnt/β-catenin signaling -- Changes in EGFR, RAS, and MAPK signaling -- (Secreted) Immunosuppressive molecules -- Tumor cell extrinsic resistance to immunotherapy -- Immunosuppressive cells and molecules -- T cells -- MDSCs -- TAMs -- T-cell dysfunction -- Metabolic shifts in tumor cells affecting the TME -- Abnormal neovascularization -- Host-related factors -- The gut microbiome -- Gut microbiota and the intestinal mucosal immune system.
,
The modulatory effect of gut microbiome on cancer immunotherapies -- Age, biological sex, and obesity -- Conclusion -- References -- Chapter 2: Biomarker-based immunotherapy in breast cancer -- Introduction -- Predictive biomarkers for tailoring patient selection -- PD-L1 -- Harmonization of the diagnostic strategies for the PD-L1 assessment -- Rationale for PD-L1 assessment based on SP142 and 22C3 assays -- Challenges and overcoming strategies -- Mismatch repair and microsatellite instability -- Conclusions -- Acknowledgments -- References -- Chapter 3: Immunotherapy for breast cancer: New strategies to enhance the patient selection and overcome therapeutic resis -- Introduction -- The immune system in BC -- Immune elimination, equilibrium, and escape -- Tumor-infiltrating lymphocytes -- Immunogenic properties of BC -- Immunotherapy of BC -- Immunotherapy in triple-negative BC -- Immunotherapy in HER2+ BCs -- Immunotherapy in HR+ BCs -- Immunotherapy in BRCA (BC gene)-mutated BC -- Patterns of clinical response to immunotherapy -- Biomarkers of response to immunotherapy -- Tumor-associated features that can predict cancer antigenicity -- Immune system-related predictors of benefit from immunotherapy -- Novel approaches -- Resistance to immunotherapy -- Cancer cell-intrinsic mechanisms of resistance: The presentation of the antigen -- Cancer cell-intrinsic mechanisms of resistance: The oncogenic activation of various signaling pathways -- Cancer cell-extrinsic mechanisms of resistance: Immunosuppressive TME and exhausted T cells -- Cancer cell-extrinsic mechanisms of resistance: Characteristics of the host -- Strategies to overcome immunoresistance -- Increasing tumor immunogenicity and T-cell priming -- Overcoming T-cell exhaustion -- Improving tumor immune microenvironment -- Combination with target therapy -- Epigenetic modulation.
,
Enhancing tumor infiltration by T cells -- Microbiome -- Future perspectives -- References -- Chapter 4: Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers -- Introduction -- Gastroesophageal cancer -- PD-L1 -- MMR/MSI -- EBV -- TMB -- Other biomarkers for combinatorial therapies with ICIs -- Her2 -- CLDN18.2 -- Small bowel and colorectal cancer -- MMR/MSI -- TMB -- Anal cancer -- PD-L1 -- TILs -- TMB -- MMR/MSI -- Biliopancreatic cancers -- MMR/MSI -- TMB -- Gastroenteropancreatic neuroendocrine neoplasms -- MMR/MSI -- PD-L1 -- Conclusions -- References -- Chapter 5: Immunotherapeutic strategies in hepatopancreatobiliary cancers -- Hepatocellular carcinoma -- Introduction -- PD-L1 -- TMB -- MSI status -- Gene mutations -- Gut microbiome -- Pancreatic cancer -- Introduction -- Predictive immune biomarkers -- Looking for the holy grail of PDAC immunotherapy -- Biliary tract cancer (BTC) -- Introduction -- Tumor-immune microenvironment of BTC -- Immune checkpoint inhibitors in BTC management -- Predictive biomarkers -- Perspectives on how to increase the success of immunotherapy in BTC -- References -- Chapter 6: Immunotherapeutic strategies for the treatment of colorectal cancer -- Introduction -- ICIs in dMMR/MSI-H mCRC -- Rationale for the use of ICIs in dMMR/MSI-H mCRC -- Approved treatments and ongoing studies in dMMR/MSI-H mCRC -- Mechanisms of primary and secondary resistance to ICIs in dMMR/MSI-H mCRC patients -- MSI testing and radiological assessment -- Site of metastatic disease -- Immune-related molecular biomarkers -- ICIs in MSS mCRC -- The challenge of ICIs in MSS mCRC -- How to overcome primary and secondary resistance to ICI in MSS and MSI mCRC -- Combination of ICIs, antiangiogenic agents, with or without chemotherapy.
,
Combination of ICIs, tyrosine kinase inhibitors, with or without chemotherapy -- Rationale and clinical trials of ICI combination with anti-EGFR antibodies -- Rationale and clinical trials of PD1/PD-L1 with or without CTLA4 and LAG3 ICI -- Adoptive cell transfer therapy (ACT) and tumor vaccines -- Immunotherapy in early colorectal cancer -- Neoadjuvant therapy for MSI/dMMR tumors -- Adjuvant therapy for MSI/dMMR tumors -- Immunotherapy for localized tumors beyond MSI/dMMR -- Predictive factors of response to immunotherapy in colorectal cancer and biomarkers for patients selection -- Tumor mutational burden and PD-L1 expression -- Tumor-infiltrating lymphocytes, immunoscore -- POLE, consensus molecular subtype and other gene signatures -- Microbiome -- References -- Chapter 7: Immunotherapeutic strategies in gastroesophageal tumors -- Introduction -- The role of immunotherapy in early-stage GEC -- Immunotherapy for advanced GEC -- Esophageal squamous cell carcinoma -- First-line treatment -- Second and further lines of treatment -- Esophageal, gastric, and GEJ adenocarcinoma -- First-line treatment -- Later lines of treatment -- Mechanisms of resistance and further perspectives -- Conclusions -- References -- Chapter 8: Concluding remarks and future perspectives -- Index.
Weitere Ausg.:
Print version: Ghidini, Michele Principles of Immunotherapy in Breast and Gastrointestinal Cancers San Diego : Elsevier Science & Technology,c2024 ISBN 9780443133763
Sprache:
Englisch
Bookmarklink
